Minh Truong Do, Ph.D.
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Thoracic Head/Neck Medical Oncology-Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2014 | Chungnam National University, Daejeon, Biological Pharmacy, Ph.D |
Postgraduate Training
| 2018-2021 | Postdoctoral Fellow, Cancer Biology, Immuno-genomics, Lung Cancer, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2018 | Postdoctoral fellow, Molecular Pharmacology, Small G proteins, Duke-NUS Medical School |
Licenses & Certifications
| 2007 | Pedagogical Certificate |
Experience & Service
Faculty Academic Appointments
Instructor, Thoracic-Head & Neck Med Onc, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - 2026
Lecturer, Faculty of Biotechnology, Thai Nguyen University of Sciences, Thai Nguyen, Vietnam, 2008 - 2016
Intramural Institutional Committee Activities
Committee member, CPRIT TRIUMPH Postdoctoral Fellow Meeting, The University of Texas MD Anderson Cancer Center, 2025
Honors & Awards
| 2017 | Khoo Postdoctoral Fellowship Award, Singapore Healthcare Clusters including Duke-NUS Medical School |
| 2013 | Brain Korea 21 Plus Fellowship Award for Leading Universities and Students, Korean Government |
| 2011 | Brain Korea 21 Fellowship Award for Leading Universities and Students, Korean Government |
| 2002 | Winner of 3rd Prize Provincial excellent student in biology |
Selected Presentations & Talks
Local Presentations
- 2025. Understanding and harnessing immune-modulatory effects of pan-RAS(ON) inhibitor RMC-7977 to target RBM10 deficiency in KRAS-driven non-small cell lung cancer. Poster. 2025 THNMO Research Retreat. Houston, Texas, US.
- 2024. Loss of RBM10 drives KRAS-mutant non-small cell lung cancer progression via macrophages-mediated immune suppression. Invited. 2024 THNMO Research Retreat. Houston, Texas, US.
International Presentations
- 2014. Metformin Inhibits Aryl Hydrocarbon Receptor-Mediated Induction of CYP1A1 and CYP1B1 in Breast Cancer Cells. Poster. The 53rd Annual Meeting of Society of Toxicology,Phoenix. 2014. Phoenix, US.
- 2013. Mollugin Inhibits Proliferation and Induces Apoptosis by Inhibiting HER2 Expression in HER2-Overexpressing Breast and Ovarian Cancer Cells. Poster. The 52nd Annual Meeting of Society of Toxicology 2013. San Antonio, US.
- 2012. Prevention of high glucose-induced hepatic lipogenesis by phillyrin through AMP-activated protein kinase signaling pathway. Poster. The 51st Annual Meeting of Society of Toxicology 2012. San Francisco, US.
Grant & Contract Support
| Date: | 2023 - 2028 |
| Title: | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA279452 |
| Date: | 2023 - 2028 |
| Title: | Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA272570 |
| Date: | 2023 - 2028 |
| Title: | Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA279194 |
| Date: | 2022 - 2025 |
| Title: | Evaluating the antitumor efficacy of RAS(ON) inhibitors in immune competent models of KRAS-mutant NSCLC |
| Funding Source: | Revolution Medicines Inc |
| Role: | Co-I |
| ID: | 00061685 |
| Date: | 2021 - 2026 |
| Title: | Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA262469 |
| Date: | 2021 - 2028 |
| Title: | Dr. Skoulidis Lab Study of RCT |
| Funding Source: | Mirati Therapeutics, Inc |
| Role: | Co-I |
| ID: | 59451 |
| Date: | 2020 - 2023 |
| Title: | Elucidating aberrant splicing-induced immune pathway activation in RBM10-deficient KRAS-mutant NSCLC and harnessing its potential for precision immunotherapy |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP200287 |
| Date: | 2017 - 2018 |
| Title: | Isoprenylcysteine carboxylmethyltransferase regulates RAB4A-mediated integrin β3 recycling and cancer metastasis |
| Funding Source: | Singapore Healthcare clusters including Duke-NUS Medical School |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Galan-Cobo A, Vokes NI, Qian Y, Molkentine D, Ramkumar K, Paula AG, Pisegna M, McGrail DJ, Poteete A, Cho S, Do MT, Karimi A, Kong Y, Solanki A, Karmokar A, Floc'h N, Hughes A, Sargeant R, Young L, Shen L, Kar G, Keshvani C, Arrechedera C, Hernandez S, Schlacher K, Wang J, Iyer S, Conway J, Keddar MR, Milo M, de Toma I, Critchlow SE, Barrett JC, Cosaert J, Lau A, Valge-Archer V, Byers LA, Barry ST, Heymach JV. KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer Cell 43(8):1530-1548.e9, 2025. e-Pub 2025. PMID: 40645185.
- Do M. RBM10 deficiency drives tumorigenesis of KRAS-mutant non-small cell lung cancer and therapeutic strategy leverages the immune-modulatory effects of pan-RAS(ON) inhibitor. e-Pub 2025.
- Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov 14(11):2183-2208, 2024. e-Pub 2024. PMID: 38975897.
- Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
- Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
- Do MT, Chai TF, Casey PJ, Wang M. Isoprenylcysteine carboxylmethyltransferase function is essential for RAB4A-mediated integrin β3 recycling, cell migration and cancer metastasis. Oncogene 36(41):5757-5767, 2017. e-Pub 2017. PMID: 28604748.
- Kim HG, Kim YR, Park JH, Khanal T, Choi JH, Do MT, Jin SW, Han EH, Chung YH, Jeong HG. Endosulfan induces COX-2 expression via NADPH oxidase and the ROS, MAPK, and Akt pathways. Arch Toxicol 89(11):2039-50, 2015. e-Pub 2015. PMID: 25199686.
- Do MT, Kim HG, Tran TT, Khanal T, Choi JH, Chung YC, Jeong TC, Jeong HG. Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. Toxicol Appl Pharmacol 280(1):138-48, 2014. e-Pub 2014. PMID: 25110054.
- Do MT, Kim HG, Choi JH, Jeong HG. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic Biol Med 74:21-34, 2014. e-Pub 2014. PMID: 24970682.
- Do MT, Na M, Kim HG, Khanal T, Choi JH, Jin SW, Oh SH, Hwang IH, Chung YC, Kim HS, Jeong TC, Jeong HG. Ilimaquinone induces death receptor expression and sensitizes human colon cancer cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38 MAPK-CHOP signaling pathways. Food Chem Toxicol 71:51-9, 2014. e-Pub 2014. PMID: 24930757.
- Choi JH, Jin SW, Han EH, Park BH, Kim HG, Khanal T, Hwang YP, Do MT, Lee HS, Chung YC, Kim HS, Jeong TC, Jeong HG. Platycodon grandiflorum root-derived saponins attenuate atopic dermatitis-like skin lesions via suppression of NF-κB and STAT1 and activation of Nrf2/ARE-mediated heme oxygenase-1. Phytomedicine 21(8-9):1053-61, 2014. e-Pub 2014. PMID: 24854572.
- Khanal T, Kim HG, Do MT, Choi JH, Won SS, Kang W, Chung YC, Jeong TC, Jeong HG. Leptin induces CYP1B1 expression in MCF-7 cells through ligand-independent activation of the ERα pathway. Toxicol Appl Pharmacol 277(1):39-48, 2014. e-Pub 2014. PMID: 24631339.
- Khanal T, Kim HG, Do MT, Choi JH, Chung YC, Kim HS, Park YJ, Jeong TC, Jeong HG. Genipin induces cyclooxygenase-2 expression via NADPH oxidase, MAPKs, AP-1, and NF-κB in RAW 264.7 cells. Food Chem Toxicol 64:126-34, 2014. e-Pub 2014. PMID: 24296130.
- Choi JH, Hwang YP, Kim HG, Khanal T, Do MT, Jin SW, Han HJ, Lee HS, Lee YC, Chung YC, Jeong TC, Jeong HG. Saponins from the roots of Platycodon grandiflorum suppresses TGFβ1-induced epithelial-mesenchymal transition via repression of PI3K/Akt, ERK1/2 and Smad2/3 pathway in human lung carcinoma A549 cells. Nutr Cancer 66(1):140-51, 2014. e-Pub 2014. PMID: 24341702.
- Do MT, Kim HG, Choi JH, Khanal T, Park BH, Tran TP, Jeong TC, Jeong HG. Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. Food Chem 141(3):2591-9, 2013. e-Pub 2013. PMID: 23870999.
- Do MT, Kim HG, Khanal T, Choi JH, Kim DH, Jeong TC, Jeong HG. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Toxicol Appl Pharmacol 271(2):229-38, 2013. e-Pub 2013. PMID: 23707609.
- Hwang YP, Kim HG, Choi JH, Do MT, Chung YC, Jeong TC, Jeong HG. S-allyl cysteine attenuates free fatty acid-induced lipogenesis in human HepG2 cells through activation of the AMP-activated protein kinase-dependent pathway. J Nutr Biochem 24(8):1469-78, 2013. e-Pub 2013. PMID: 23465592.
- Do MT, Hwang YP, Kim HG, Na M, Jeong HG. Mollugin inhibits proliferation and induces apoptosis by suppressing fatty acid synthase in HER2-overexpressing cancer cells. J Cell Physiol 228(5):1087-97, 2013. e-Pub 2013. PMID: 23065756.
- Pil Hwang Y, Gyun Kim H, Choi JH, Truong Do M, Tran TP, Chun HK, Chung YC, Jeong TC, Jeong HG. 3-Caffeoyl, 4-dihydrocaffeoylquinic acid from Salicornia herbacea attenuates high glucose-induced hepatic lipogenesis in human HepG2 cells through activation of the liver kinase B1 and silent information regulator T1/AMPK-dependent pathway. Mol Nutr Food Res 57(3):471-82, 2013. e-Pub 2013. PMID: 23349077.
- Choi JH, Kim HG, Jin SW, Han EH, Khanal T, Do MT, Hwang YP, Choi JM, Chun SS, Chung YC, Jeong TC, Jeong HG. Topical application of Pleurotus eryngii extracts inhibits 2,4-dinitrochlorobenzene-induced atopic dermatitis in NC/Nga mice by the regulation of Th1/Th2 balance. Food Chem Toxicol 53:38-45, 2013. e-Pub 2013. PMID: 23200891.
- Do MT, Kim HG, Choi JH, Khanal T, Park BH, Tran TP, Hwang YP, Na M, Jeong HG. Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/AMP-activated protein kinase-dependent signalling. Food Chem 136(2):415-25, 2013. e-Pub 2013. PMID: 23122079.
- Han EH, Yang JH, Kim HK, Choi JH, Khanal T, Do MT, Chung YC, Lee KY, Jeong TC, Jeong HG. 1-Bromopropane up-regulates cyclooxygenase-2 expression via NF-κB and C/EBP activation in murine macrophages. Food Chem Toxicol 50(5):1616-22, 2012. e-Pub 2012. PMID: 22353212.
- Khanal T, Kim HG, Choi JH, Do MT, Kong MJ, Kang MJ, Noh K, Yeo HK, Ahn YT, Kang W, Kim DH, Jeong TC, Jeong HG. Biotransformation of geniposide by human intestinal microflora on cytotoxicity against HepG2 cells. Toxicol Lett 209(3):246-54, 2012. e-Pub 2012. PMID: 22245672.
- Khanal T, Kim HG, Choi JH, Park BH, Do MT, Kang MJ, Yeo HK, Kim DH, Kang W, Jeong TC, Jeong HG. Protective role of intestinal bacterial metabolism against baicalin-induced toxicity in HepG2 cell cultures. J Toxicol Sci 37(2):363-71, 2012. e-Pub 2012. PMID: 22467027.
Other Articles
- Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, S, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, MC, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, JE, Leighl, NB, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV Correction to. Nature 639(8054):E19, 2025. PMID: 40016449.
- Do M RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma. PMID: 42102809.
Abstracts
- Do M. Loss of RBM10 drives KRAS-mutant non-small cell lung cancer progression via macrophages-mediated immune suppression. AACR Annual Meeting 2026.
Patient Reviews
CV information above last modified September 04, 2026